Category Archives: Embryonic Stem Cells


Stem Cell Clinic > Embryonic Stem Cells

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Embryonic Stem Cells

DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

More:
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By Embryonic Stem Cells

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.

Here is the original post:
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

By Embryonic Stem Cells

Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated Financial Statements as well as the report on non-financial matters for the 2024 financial year. The 1,072 shareholders in attendance, together with the votes represented by the independent proxy, represented 75.73% of shares registered with voting rights.

Read the original:
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough

By Embryonic Stem Cells

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced a major advancement in vascularized tissue engineering. A newly published study in ACS Biomaterials Science & Engineering demonstrates how FRESH™ 3D bioprinting, combined with sacrificial gelatin microparticles, significantly enhances cell viability in thick tissue constructs by improving nutrient diffusion and enabling scalable perfusion strategies.

See the rest here:
FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage…

By Embryonic Stem Cells

MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibitors (ICI) in first line small cell lung cancer (SCLC) patients with extensive disease, sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health. This is the first clinical trial testing the combination of iadademstat with ICI.

More:
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage...

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

By Embryonic Stem Cells

HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced that Dr. David Young, Founder and President of Research & Development, has been invited to present at the World Orphan Drug Congress USA 2025.

Read more:
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

Aspargo Labs CEO to Participate in Panel Discussion at the American Urological Association Innovation Nexus Conference

By Embryonic Stem Cells

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a Pharmaceutical and MedTech company focused on converting the world's most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced that Michael Demurjian, CEO & Chairman, will participate in a panel discussion at the American Urological Association (AUA) Innovation Nexus Conference in Las Vegas, Nevada, taking place on April 25, 2025.

Originally posted here:
Aspargo Labs CEO to Participate in Panel Discussion at the American Urological Association Innovation Nexus Conference

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

By Embryonic Stem Cells

WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates.

See original here:
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

←